Grants for State governments - Federal

This funding opportunity supports innovative research projects aimed at developing new treatments for Duchenne muscular dystrophy, targeting both new and established researchers in the field.

This program provides funding to state and local educational agencies to increase the number of qualified mental health professionals in schools, particularly in high-need areas, to support student mental wellness and safe learning environments.

The "Ending the HIV Epidemic in the U.S. Technical Assistance Provider" grant aims to fund technical assistance and systems coordination to help reduce new HIV infections in specific U.S. jurisdictions by diagnosing, treating, and preventing HIV, and responding to outbreaks, using innovative strategies and coordinating existing and new resources.

This SNOFO has been updated for Fiscal Year (FY) 2024 competition. The Office of Refugee Resettlement (ORR) has modified: Executive Summary, Section I. Program Description; Section II. Federal Award Information; Section IV.1. Address to Request Application Package; Section IV.4. Submission Dates and Times; and Section. VII. HHS Award Agency Contact(s). The Office of Refugee Resettlement (ORR), within the Administration for Children and Families, provides temporary shelter care and other child welfare-related services to Unaccompanied Children (UC) in ORR custody. Residential care services begin once ORR accepts a UC for placement and end when the minor is released from ORR custody, turns 18 years of age, or the minors immigration case results in a final disposition of removal from the United States. Residential care and other child welfare-related services are provided by state child placement licensed residential care programs in the least restrictive setting appropriate for the UCs age and special needs. ORR is announcing the availability of funds under this Standing Notice of Funding Opportunity (SNOFO) to seek residential care providers, including shelter, group home, and transitional foster care. At the time of application, applicants do not have to be licensed by an appropriate licensing agency to provide residential shelter, group, or foster care services for children. However, applicants must be prepared to obtain the appropriate state child placement and facility licensure post-award. All entities funded under this SNOFO are subject to the provisions of the Service Contract Act (SCA) and implementing regulations found in title 29 of the C.F.R. Part 4 including SCA labor standard clauses and must abide by applicable wage determinations. For further information on wage determination, please visit https://alpha.sam.gov/content/wage-determinations. This award is also subject to Executive Order 14026 Increasing the Minimum Wage for Federal Contractors, and its implementing regulations at 29 C.F.R. Part 23; and Executive Order 13706, Establishing Paid Sick Leave for Federal Contractors, and its implementing regulations at 29 C.F.R. Part 13. For additional information on the Minimum Wage and Paid Sick Leave requirements, please visit: https://www.dol.gov/agencies/whd/government-contracts/minimum-wage and https://www.dol.gov/agencies/whd/government-contracts/sick-leave. All entities, funded under this SNOFO, must also comply with the Flores Settlement Agreement Case No. CV 85-4544-RJK (C.D. Cal. 1996), pertinent regulations, laws, and ORR policies, instructions, and procedures including, but not limited to, the ORR Policy Guide and Manual of Procedures. ORR encourages applicants to review ORR's policies, instructions, and procedures at: http://www.acf.hhs.gov/programs/orr/resource/children-entering-the-united-states-unaccompanied as these will be critical to the overall program design. Please refer to the SNOFO when it publishes for more details on licensing timeframes, application closing dates and project periods.

This funding opportunity supports researchers investigating new biological, environmental, and social factors contributing to liver cancer in the U.S., particularly in relation to established risk factors and health disparities.

This funding opportunity supports community-based arts programs designed to enhance the health and well-being of military personnel, veterans, and their families through creative engagement.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites U01 cooperative agreement applications for Physical Sciences-Oncology Network (PS-ON). The goal of the PS-ON is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The research projects funded through this FOA, individually and as a collaborative Network along with other funded research projects, will support transdisciplinary research that: (1) drives a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to support the archiving and documentation of existing data sets within the scientific mission of the NICHD in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in July 2024 with an expected application due date in October 2024. This NOFO will utilize the R03 activity code. Details of the planned NOFO are provided below.

This funding opportunity is designed to help state agencies implement a collaborative approach that integrates mental health and substance use treatment into primary care settings, improving access to behavioral health services.

This funding opportunity provides financial support to nonprofit organizations and other eligible entities to develop innovative projects that strengthen trade and investment ties between the United States and Africa, promoting economic growth and collaboration.

The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa. A number of Gram-negative bacterial pathogens are associated with the alarming increase in rates of drug resistance in healthcare and community settings. This group includes carbapenem-resistant Acinetobacter , carbapenem-resistant Enterobacterales (CRE), and MDR Pseudomonas aeruginosa that have been designated as “urgent” or “serious” threats in a recent report by the Centers for Disease Control and Prevention (CDC). A significant threat arises from the lack of effective therapeutic options available to treat some of these infections and is exacerbated by the scarcity of novel compounds effective against antimicrobial resistant (AR) and multidrug-resistant (MDR) Gram-negative bacteria in the discovery and development pipeline. In recent years, several public forums (including NIAID-sponsored workshops) identified the lack of understanding of the principles that govern compound penetration into, and efflux out of, Gram-negative bacteria as a key bottleneck for the rational discovery of novel lead therapeutic compounds. The paucity of suitable assays/tools/models to inform structure-activity relationships and guide optimization of whole cell penetration (and efflux avoidance) is reflected in the failure of medicinal chemistry efforts to advance novel chemical classes of compounds with Gram-negative activity. As more Gram-negative bacteria become resistant to antimicrobials and therapeutic options become limited or nonexistent, it becomes imperative to understand and rationalize the principles that allow molecules to penetrate Gram-negative bacteria, while avoiding efflux and overt toxicity toward eukaryotic cells. Therefore, developing new assays, tools, and models is paramount for overcoming this key bottleneck and facilitating the development of novel compounds targeting Gram-negative pathogens. Research Objectives and Scope The objective of this NOFO is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens. This NOFO also supports the preclinical development of novel Gram-negative antibacterial therapeutics based on the tools and models hereby developed. Applications must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and/or MDR Pseudomonas aeruginosa. Projects should complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria. This NOFO will also support subsequent preclinical development of a promising lead antibacterial. Given the complex challenges of this research, this initiative encourages applications from multi-disciplinary teams composed of relevant experts in areas such as bacterial physiology, microbiology, bacterial membrane biology, medicinal chemistry, pharmacology, computation, and specialized technologies (microscopy, spectroscopy, electrophysiology, machine learning, etc.), as appropriate. Collaboration with, and utilization of, the NIAID Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB), is recommended for completion of project relevant medicinal chemistry tasks. Close collaboration between academic and industry partners is highly encouraged to optimally combine innovative basic science with drug discovery expertise and proper access to compound libraries more typically available from industry. Examples of assay and model development activities include, but are not limited to: Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard minimum inhibitory concentration (MIC) testing; Innovative quantitative assays to measure drug concentrations in the bacterial cytoplasm and/or periplasmic space; Innovative technologies for dissecting and assessment of the kinetics of drug penetration and efflux from bacteria; and Computational algorithms for describing/predicting physical-chemical properties/guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance. Applicants should demonstrate the utility of the developed tools and/or assays to predict and measure potency of candidate therapeutics against Gram-negative targets through one or more approaches. For example, using the developed models and/or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity; or profiling existing libraries of compounds with known Gram-negative activity. Applications including the following will be considered non-responsive and will not be reviewed: Projects that do not focus on at least one select Gram-negative pathogen (carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, or MDR Pseudomonas aeruginosa); Projects focused only on Gram-positive bacteria or Mycobacterium tuberculosis; Projects that do not focus on penetration and efflux of small molecules; Applications not containing a Milestone and Timeline attachment; Applications proposing Clinical trials; and Research on HIV/AIDS.

This program provides financial assistance to state and territorial governments to strengthen their emergency management capabilities and improve preparedness for all types of hazards.

This funding opportunity supports researchers in developing innovative animal models and biological tools to advance the understanding of Down syndrome and its related health conditions.

This program provides funding to state and local governments with accredited crime laboratories to improve their DNA analysis capabilities, reduce case backlogs, and enhance public safety through the use of advanced DNA technology.

This funding opportunity provides financial support to various organizations for projects that promote the use of wood products and energy, enhance forest health, and stimulate economic growth in forested communities across the U.S.

This funding opportunity supports innovative research projects that explore how climate change affects cancer risks, treatment, and survivorship, with a focus on developing solutions to mitigate these impacts and address health inequities.

The "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that further develop and validate innovative technologies for analyzing molecular and cellular aspects of cancer, with the goal of improving cancer research, detection, diagnosis, treatment, and understanding of health disparities.

This grant provides funding for researchers to investigate the biological mechanisms behind adverse effects related to anti-beta-amyloid immunotherapy in Alzheimer's disease, with the goal of developing strategies to protect the blood-brain barrier and improve treatment safety.

This funding opportunity supports U.S.-based organizations in developing and testing effective cancer interventions that improve health outcomes for diverse populations across the entire cancer control continuum, particularly in under-resourced communities.

This grant provides funding to state, tribal, and local law enforcement agencies to enhance their ability to investigate and prosecute cybercrimes against individuals, while partnering with victim service providers to improve support for victims.